There are literally thousands of old, U.S. Food and Drug Administration (FDA) approved drugs that may have other potential uses besides the conditions for which they were approved. The trouble it: nobody has the profit motive to fully investigate them. Even when there are studies the FDA is suspect. The agency understands there will be little monitoring or follow-up studies reviewing long-term efficacy.
Managed Competition Exposed
You can find competing private health insurance plans with community rated premiums and government sponsored risk adjustment in Belgium, Germany, Israel, the Netherlands and Switzerland – where participation is mandatory. Ireland and Australia have voluntary enrollment, as does Medicare Advantage and the (Obamacare) marketplaces in the United States.
Wokeness Invades the Doctor’s Office
This is Dr. Stanley Goldfarb in the Wall Street Journal:
The National Library of Medicine database shows more than 2,700 recent papers on “racism and medicine,” which generally purport to show physician bias leading to racial disparities in health outcomes. Yet the most commonly cited studies are shoddily designed, ignore such critical factors as pre-existing conditions, or reach predetermined and sensationalized conclusions that aren’t supported by reported results. These papers in turn are used to source even more shoddy research.
Consumer Reports: Mail order may be cheaper when shopping for drugs
Nearly two-thirds of adults (62%) take at least one prescription drug. Of Americans on a drug, nearly one-third (30%) report either not filling a prescription or not taking it as directed due to the cost. Even people with prescription drug coverage often find drug copays are costly. According to Kaiser Family Foundation, the average copay for a generic drug is only $12 but many copays are much higher.